Related Experiment Video

Updated: Aug 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

[A case-control study on the mxA polymorphisms and susceptibility to severe acute respiratory syndromes]

Hong-wei Wang1, Jing He, Pan-he Zhang

  • 1Epidemiological Department of Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.

Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|January 5, 2006
PubMed
Abstract

Insights

Genetic variations in the myxovirus resistance 1 (MxA) gene promoter are linked to increased susceptibility to severe acute respiratory syndrome (SARS). The T/G polymorphism at position-88 in the MxA gene may confer genetic risk for SARS in the Chinese Han population.

Area of Science:

  • Genetics
  • Virology
  • Immunology

Context:

  • Severe Acute Respiratory Syndrome (SARS) is a highly contagious respiratory illness.
  • Understanding host genetic factors influencing SARS susceptibility is crucial for public health.
  • The myxovirus resistance 1 (MxA) gene plays a role in innate antiviral immunity.

Purpose:

  • To investigate the association between genetic polymorphisms in the myxovirus resistance 1 (MxA) gene and susceptibility to SARS.
  • To identify specific MxA gene variants that may increase the risk of developing severe SARS.
  • To analyze the T/G polymorphism at position-88 in the MxA gene promoter.

Summary:

  • A case-control study utilized polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to examine the MxA gene promoter T/G polymorphism.
  • Results indicated a significantly higher proportion of the GT genotype in SARS cases compared to controls (81.3% vs. 62.5%).
  • Multivariate analysis confirmed the association between the MxA promoter-88G/T single nucleotide polymorphism (SNP) and SARS susceptibility, even after adjusting for protective measures.

Impact:

  • The MxA promoter-88G/T SNP may contribute to host genetic susceptibility to SARS.
  • Findings suggest that genetic predisposition could be a factor in SARS development.
  • This research provides insights into the genetic underpinnings of SARS, potentially informing future risk assessment strategies.

More Related Videos

Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein09:39

Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein

Published on: April 21, 2015

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: